title: Comparison of fluconazole with oral polyenes in the prevention of fungal infections in neutropenic patients. A prospective, randomized, single-center study.
abstract: The goal of this prospective randomized single-center study was the comparison of safety and efficacy of high-dose oral/intravenous fluconazole (400 mg daily) (group A) with oral nystatin plus miconazole inhalations (group B) in the prevention of fungal infections on a hemato-oncological isolation Ward. Of 157 patients admitted to the isolation ward during the study period only 90 (57%) were eligible for randomization; 22 (14%) had a fungal infection at admission. Of the 90 randomized patients, 89 were evaluable, 43 in group A and 46 in group B. The age, sex, diagnosis, planned therapy and risk factors for fungal infections at admission as well as the duration of neutropenia were in the same proportions in both groups. Oral thrush and mucocutaneous candidiasis were prevented in all patients of both groups, and 29 patients (32%: 17 in group A, 12 in group B) were discharged after successful prophylaxis (NS). Empiric amphotericin B was given according to predetermined criteria to 45 patients (51%: 23 group A, 22 group B; NS). Fluconazole significantly delayed the time before the start of intravenous amphotericin B. It was begun after a median of 10 days (0-45 days, range) of neutropenia below 0.5 x 10(9) granulocytes/l in group A and 7.5 days (0-26, range) in group B (P < 0.05). The duration of successful prophylaxis was significantly longer in group A (26 days median) than in group B (21 days, median) (P < 0.05). Systematic fungal infection was documented in 3 patients (1 group A, 2 group B; NS).
authors.affiliation: Department of Internal Medicine, University Hospital, Basel, Switzerland.
authors.forename: T
authors.initials: T
authors.lastname: Egger
authors.forename: A
authors.initials: A
authors.lastname: Gratwohl
authors.forename: A
authors.initials: A
authors.lastname: Tichelli
authors.forename: M
authors.initials: M
authors.lastname: Uhr
authors.forename: C
authors.initials: C
authors.lastname: Stebler Gysi
authors.forename: J
authors.initials: J
authors.lastname: Passweg
authors.forename: M
authors.initials: M
authors.lastname: Pless
authors.forename: M
authors.initials: M
authors.lastname: Wernli
authors.forename: U
authors.initials: U
authors.lastname: Buser
authors.forename: J
authors.initials: J
authors.lastname: Wuhrmann
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D005260:Female; D015725:Fluconazole / Q000008:administration & dosage*; D006801:Humans; D016867:Immunocompromised Host; D008297:Male; D008825:Miconazole / Q000008:administration & dosage; D008875:Middle Aged; D009181:Mycoses / Q000517:prevention & control*; D009503:Neutropenia / Q000150:complications*; D009761:Nystatin / Q000008:administration & dosage*; D011446:Prospective Studies
chemical_list: D009761:Nystatin; D008825:Miconazole; D015725:Fluconazole